Get the Stockscreener App
50.72
0.56%
0.28
After Hours:
50.41
-0.31
-0.61%
Royalty Pharma Plc stock is traded at $50.72, with a volume of 3.89M.
It is up +0.56% in the last 24 hours and up +7.19% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$50.44
Open:
$51.29
24h Volume:
3.89M
Relative Volume:
1.16
Market Cap:
$22.54B
Revenue:
$2.38B
Net Income/Loss:
$1.32B
P/E Ratio:
28.48
EPS:
1.7806
Net Cash Flow:
$897.24M
1W Performance:
+2.49%
1M Performance:
+7.19%
6M Performance:
+24.37%
1Y Performance:
+57.96%
1-Day Range:
$49.74
$51.65
1-Week Range:
$49.11
$51.65
52-Week Range:
$32.15
$51.65
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
50.72 | 22.41B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma’s Earnings Call Signals Confident Growth - TipRanks
Royalty Pharma Q1 Earnings Call Highlights - MarketBeat
MSN Money - MSN
Royalty Pharma plc Q1 2026 Financial Results: Earnings, Revenue, and Risk Factors from Latest 10-Q Filing - Minichart
Royalty Pharma Q1 2026 earnings preview - MSN
Royalty Pharma plc Q1 2026 Earnings Call Summary - Yahoo Finance
Royalty Pharma raises 2026 portfolio receipts guidance to $3.325B-$3.45B as it scales R&D co-funding - MSN
Royalty Pharma Reports 10% Growth in Portfolio Receipts for Q1 2026 Driven by Strong Product Performance - Minichart
RPRX vs. AMGN: Which Stock Is the Better Value Option? - Yahoo! Finance Canada
Royalty Pharma Q1 2026 slides: double-digit growth, guidance raised - Investing.com
Royalty Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Royalty Pharma (RPRX) Valuation Check As Q1 Earnings Expectations Drive Strong Share Price Momentum - Sahm
Royalty Pharma Q1 2026 slides: double-digit growth, guidance raised By Investing.com - Investing.com India
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: Royalty Pharma Q1 2026 shows robust growth - Investing.com
Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Royalty Pharma (NASDAQ: RPRX) grows Q1 2026 profit and cash flow - Stock Titan
Royalty Pharma plc 2026 Q1ResultsEarnings Call Presentation (NASDAQ:RPRX) 2026-05-06 - Seeking Alpha
Earnings Flash (RPRX) Royalty Pharma plc Reports Q1 Revenue $631.0M - marketscreener.com
Royalty Pharma : Q1 2026 Financial Results Presentation - marketscreener.com
Royalty Pharma (Nasdaq: RPRX) posts strong Q1 2026 growth and raises full-year guidance - Stock Titan
Royalty Pharma PLC $RPRX Position Reduced by Swedbank AB - MarketBeat
Royalty Pharma reports first quarter 2026 results - The Manila Times
Royalty Pharma commits up to $1.25B to new deals, lifts 2026 outlook - Stock Titan
RPRX|Royalty Pharma PLC|Price:50.440|Chg%:0.24 - TradingKey
Royalty Pharma stock hits 52-week high at 50.49 USD By Investing.com - Investing.com South Africa
Royalty Pharma earnings in focus as deal activity accelerates By Investing.com - Investing.com South Africa
Royalty Pharma to Announce Q1 Earnings on May 6 - Intellectia AI
Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week HighStill a Buy? - MarketBeat
Royalty Pharma stock hits 52-week high at 50.49 USD - Investing.com
Royalty Pharma Plc Hits New 52-Week High of $50.47 - Markets Mojo
The Technical Signals Behind (RPRX) That Institutions Follow - Stock Traders Daily
Royalty Pharma PLC $RPRX Shares Bought by UBS Group AG - MarketBeat
Hussman Strategic Advisors Inc. Buys New Stake in Royalty Pharma PLC $RPRX - MarketBeat
PFA Pension Forsikringsaktieselskab Acquires New Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Holdings Lifted by CM Management LLC - MarketBeat
Royalty Pharma’s Q2 2026 Dividend Raises a Deeper Question About Its Capital Allocation Strategy (RPRX) - Sahm
Pictet Asset Management Holding SA Sells 62,539 Shares of Royalty Pharma PLC $RPRX - MarketBeat
RPRX Stock Price, Quote & Chart | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) - ChartMill
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares of Stock - MarketBeat
Royalty Pharma EVP & CFO Terrance Coyne disposes of $1.73m in stock - Investing.com Canada
Royalty Pharma EVP & CFO Terrance Coyne disposes of $1.73m in stock By Investing.com - Investing.com South Africa
Royalty Pharma Insider Sold Shares Worth $1,731,840, According to a Recent SEC Filing - marketscreener.com
Royalty Pharma (RPRX) CFO sells 34,791 shares under 10b5-1 plan - Stock Titan
Royalty Pharma Plc Hits New 52-Week High of $50.24 - Markets Mojo
Royalty Pharma Plc Experiences Revision in Its Stock Evaluation Amid Strong Performance - Markets Mojo
Royalty Pharma (RPRX) to Release Earnings on Wednesday - MarketBeat
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Mitsubishi UFJ Trust & Banking Corp Increases Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma stock hits 52-week high at $50.24 By Investing.com - Investing.com South Africa
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):